BlackRock Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

BlackRock Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$249K	Sell	4,111 -81	-2%	-$4.95K	﹤0.01%	2596
2016 Q3	$278K	Buy	4,192 +217	+5%	+$13.6K	﹤0.01%	2501
2016 Q2	$222K	Buy	3,975 +230	+6%	+$11.2K	﹤0.01%	2541
2016 Q1	$126K	Sell	3,745 -13,762	-79%	-$467K	﹤0.01%	2804
2015 Q4	$790K	Buy	17,507 +12,412	+244%	+$534K	﹤0.01%	1841
2015 Q3	$201K	Sell	5,095 -401	-7%	-$22.8K	﹤0.01%	2725
2015 Q2	$341K	Buy	5,496 +718	+15%	+$42.7K	﹤0.01%	2455
2015 Q1	$299K	Buy	4,778 +612	+15%	+$37.2K	﹤0.01%	2451
2014 Q4	$235K	Sell	4,166 -412	-9%	-$18.2K	﹤0.01%	2531
2014 Q3	$129K	Sell	4,578 -459	-9%	-$13.8K	﹤0.01%	2863
2014 Q2	$173K	Buy	5,037 +2,876	+133%	+$90.2K	﹤0.01%	2719
2014 Q1	$68K	Hold	2,161	–	–	﹤0.01%	3177
2013 Q4	$43K	Hold	2,161	–	–	﹤0.01%	3271
2013 Q3	$21K	Buy	2,161 +664	+44%	+$4.79K	﹤0.01%	3309
2013 Q2	$9K	Buy	+1,497	New	+$10.5K	﹤0.01%	3434

Other funds holding ANIP

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

BlackRock Advisors's ANIP Position: Q4 2016 in Review

BlackRock Advisors reduced its ANI Pharmaceuticals (ANIP) stake by 1.9% in Q4 2016, selling an estimated $4.95K and leaving 4,111 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #2596.

BlackRock Advisors first reported a position in ANIP in Q2 2013 and has held it in 15 quarters since. The position peaked at $790K in Q4 2015. 157 funds tracked by Wall St. Rank hold ANIP as of Q4 2016.

BlackRock Advisors held 4,111 shares of ANI Pharmaceuticals worth $249K as of Q4 2016.
BlackRock Advisors sold 81 ANI Pharmaceuticals shares in Q4 2016, an estimated $4.95K.
ANI Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2596 holding.
BlackRock Advisors first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's ANI Pharmaceuticals position peaked at $790K in Q4 2015.
157 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.